Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid)Nanoparticles and Nucleic Acid Adjuvants in Mice

• 作者: Yunfei Wang Jialong Qi Han Cao Cunbao Liu
• 来源期刊: 中国病毒学
• 年，卷（期）: 2021,（1）
• 所属期刊栏目: RESEARCH ARTICLES
• 页码范围: 122-132
• 页数: 11页
• 语种: 英文

摘要

The subunit herpes zoster vaccine Shingrix is superior to attenuated vaccine Zostavax in both safety and efficacy,yet its unlyophilizable liposome delivery system and the limited supply of naturally sourced immunological adjuvant QS-21 still need to be improved.Based on poly(lactic-co-glycolic acid)(PLGA)delivery systems that are stable during the lyophilization and rehydration process and using a double-emulsion(w/o/w)solvent evaporation method,we designed a series of nanoparticles with varicella-zoster virus antigen glycoprotein E(VZV-gE)as an antigen and nucleic acids including polyinosinic-polycytidylic acid(Poly I:C)and phosphodiester CpG oligodeoxynucleotide(CpG ODN),encap-sulated as immune stimulators.While cationic lipids(DOTAP)have more potential than neutral lipids(DOPC)for acti-vating gE-specific cell-mediated immunity(CMI)in immunized mice,especially when gE is encapsulated in and presented on the surface of nanoparticles,PLGA particles without lipids have the greatest potential to induce not only the highest gE-specific IgG titers but also the strongest gE-specific CMI responses,including the highest proportions of interferon-y(IFN-γ)-and interleukin-2(IL-2)-producing CD4+/CD8+T cells according to a flow cytometry assay and the greatest numbers of IFN-y-and IL-2-producing splenocytes according to an enzyme-linked immunospot(ELISPOT)assay.These results showed that immune-stimulating nucleic acids together with the PLGA delivery system showed promise as a safe and economical varicella and zoster vaccine candidate.